Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Need the shorter to close all their positions and this will fly into the £6 and beyond...
I can't seem to buy any on ii...is anybody else having the same issue?
It will be driven by market sentiment.....heavy tech NASDAQ futures look very positive..but sp is always driven by what someone really wants to pay for it based on the information they have at the time of purchase.
Nvidia smashed it...well done...I topped up slightly higher than you at 341. Should have a good day tomorrow
This will have an impact on the market as a whole.
AI is strong as will get stronger .......I think this morning drop is a natural reaction to those who wish to remove any risk to their portfolios. Remember darktrace is strong and I think we could have a bid approach either this year or early next year should Darktrace continue to perform and secure more customers.
4.20pm ET is equivalent to 9.20pm here in the UK.
Nvidia is scheduled to release its highly anticipated fiscal Q4 update after the U.S. market close on Wednesday at 4:20 PM ET, and it is expected to shatter its sales record once again amid robust demand for its AI chips.
Nasdaq had a bad day yesterday.....all focus on NViDIA.....hence the really slow start. I have topped up.
I have been invested in TLW for ages....I not a newbie...I just don't post on here too often. I just wanted to point out a downgrade to other....but also point out that the majority of analyst have this as a buy...
Not here to stir...just point out fact....by the way I don't agree with the downgrade....or majority of analyst as they don't have any real skin in the game themselves. Director buy are more important and show more confidence and we have had so.e significant buys recently...so this is still a buy for me.
They may go back into THG and BOO.... alternatively wouldn't this fit into Amazon.....they could buy...save millions with they already set up distribution. Only issue is the price....it will have to bee in the 150p plus I think.
Record first half sales of £976 million and Investing for the Future
· Doubled market share in the UK and US over the last two years. Total group sales +73% since 1H20
· Significantly enhanced target addressable market, with up to 500 million potential customers in key markets
· Integration and relaunch of four new brands in the first half, including Debenhams marketplace
· Increased warehousing and distribution capacity, capable of supporting over £4 billion of net sales
· £85 million of Adjusted EBITDA, down 5% vs. exceptional levels of profitability last year, and up +40% since 1H20, despite £26 million of freight and logistics cost inflation
· Record capital expenditure of £172 million in H1, putting in place the platform for future growth
· Opening a new distribution centre in North America in 2023, significantly strengthening our proposition
RBC Capital Markets, however, struck a more positive note, saying that the potential changes are largely in line with what was expected. James Bell, an analyst at the bank, said: “Whilst bill #10’s language on possible cancellation of mining concessions if certain clauses are contravened reads badly, we see absolutely no indication that Fresnillo is, has been or ever will be in this situation. In fact, we would argue that the group is well positioned versus peers in terms of stakeholder relations given its long history in Mexico.” He added that Fresnillo’s concessions for developments over the next two years are already in place, including its key $305m Juanicipio project. “Feedback from both Fresnillo management and other Mexican mining operators has been cautiously optimistic on AMLO’s new mines minister.” “We hope and expect sense to prevail in the country and for Fresnillo shares to recover making today’s sell-off an attractive entry point,” Bell said.
Please could someone advised as to why Immupharma have a joint broker? I can see from the RNS that it is Bryan, Garnier and Co. They look like specialist in fund raising and M and A. But I wanted to know if there were other reason for their appointment. Many Thanks in Advance
R-d-R I can assure you I not a share pumped. I am new to posting. If I have made a mistake I have always apologised. In hindsight I should have looked at the addition information that was highlighted to me. I am new to posting on boards. I will ensure future post are backed up with solid evidence before I post them. In addition I have no links to any syndicate in Asia or Mr adeel khan. With regard to my twitter.... I have stopped retweeting because I have realised that the tweet are just hearsay. I have never stated that the shareprice will be £2 soon. I hope but have never stated the price. So please take this as an apology, if that the impression I have been giving. That has never been my intention.
http://www.lanstead.co.uk/announcements/lanstead-provides-5m-aim-quoted-immupharma-support-pivotal-phase-iii-clinical-trial-lupuzor/ Lanstead have not reduced their since the Phase 3 results were made public. They must have some knowledge that ordinary holds do not have. Got to be a strong buy!
Dijon, My post was not aimed at highlighting short positions ( 28000 plus is not a massive position) I wanted to highlight the other pipeline drugs. I just getting use to putting out post so will take this away as a big "learn" Please accept my apologies.
IMMUPHARMA PLC ORDINARY SHARES UNITED K (IMMPF) Shorts Raised By 14.8% July 14, 2018 - By Theresa McIntyre IMMUPHARMA PLC ORDINARY SHARES UNITED K (OTCMKTS:IMMPF) had an increase of 14.8% in short interest. IMMPF’s SI was 28,700 shares in July as released by FINRA. Its up 14.8% from 25,000 shares previously. With 8,700 avg volume, 3 days are for IMMUPHARMA PLC ORDINARY SHARES UNITED K (OTCMKTS:IMMPF)’s short sellers to cover IMMPF’s short positions. The SI to IMMUPHARMA PLC ORDINARY SHARES UNITED K’s float is 0.03%. It closed at $0.39 lastly. It is down 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500. ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company has market cap of $. The companyÂ’s lead product candidate is the Lupuzor, which is in Phase III clinical trials for the treatment of lupus, an autoimmune chronic inflammatory disease. It currently has negative earnings. The Company’s other product candidates include IPP-204106, an anti-cancer nucleolin antagonis peptide program that has completed Phase I/IIa clinical trials to treat cancer; IPP-102199, which is in pre-clinical development stage to treat severe pain; IPP-201007 that is in early development stage for the treatment of inflammatory and allergic conditions, such as asthma and other respiratory disorders, rheumatoid arthritis, septic shock, and acute pancreatitis; and IPP-203101, a peptide antibiotic, which is in pre-clinical development stage for the treatment of lethal infections, including methicillin-resistant staphylococcus aureus and other hospital acquired infections.